Nestle SA, the world's biggest food and drink company, is beginning commercial talks with Australian pharmaceutical company Phosphagenics Ltd. to use one of its products for the treatment and prevention of metabolic syndrome.
The move underlines the Swiss company's determination to increase its focus on health foods, after its announcement last month that it will buy the medical nutrition unit of pharmaceutical giant Novartis for US$2.5 billion (Ђ1.88 billion).
Nestle Nutrition exercised its option under an existing commercial agreement to use Phospha-E for the treatment and prevention of metabolic syndrome, Phosphagenics said in a statement Friday, reports AP.
Metabolic syndrome is characterized by a variety of symptoms including abdominal obesity and elevated blood pressure.
Fearing that peace might break out with the two Koreas talking to each other, Washington instructed South Korean President to keep the message about anything but peace
The USA does not have a picture of the strong Russia, and the Americans will never allow Russians become strong. Sanctions show how obvious the conflict is
The Chinese military believe that Beijing and Moscow must resist pressure from Washington together